The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...

Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the ...

Every year, a new list of players is inducted, and this time, there are 15 finalists left, including former New York Giants quarterback Eli Manning, who is attempting to make it in his first year ...

The 19-year-old phenom, who is set to finally take over as a starter in the 2025 season, said he has been bullied by his famous uncles, Peyton and Eli, and they have even given him wedgies.

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

BofA energy sector analyst Jean Ann Salisbury thinks it's going to $180 ... It's genuinely difficult to find a Wall Street analyst with anything negative to say about Eli Lilly. CFRA Equity Analyst ...

Ayden Salisbury, fresh off his Hoosier Conference championship over the weekend, defeated Eli Bowyer by 13-0 major decision at 132 to get the Berries to within 46-28. Salisbury improved to 2-1 ...

It is the largest study ever of the drug category—which includes Novo Nordisk’s GLP-1 treatments Ozempic and Wegovy and Eli Lilly’s dual-action GLP-1/GIP agonists Mounjaro and Zepbound.